Latest From Vermillion Inc.
Test-makers and labs say the agency is missing large swaths of the market in making its "market-based" lab payment calculation, but CMS stands by its data, and finalized 2018 lab fee schedule rates. Could next steps be in Congress, or the courts?
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced June-July 2015.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Gynecological, Urological
- Ciphergen Biosystems Inc.
- North America
- Parent & Subsidiaries
- Vermillion Inc.
- Senior Management
Valerie Palmieri, Pres. & CEO
Eric Schoen, SVP, Fin. & Chief Accounting Officer
Marra Francis, MD, CMO
- Contact Info
Phone: (512) 519-0400
12117 Bee Caves Rd., Bldg. II
Austin, TX 78738
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.